Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease

Medical Hypotheses

Volumn 75, Issue 6, 2010, Pages 533-534

  Surendran, Sankar ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTOACYLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N ACETYLASPARTIC ACID; NITRIC OXIDE;

ARTICLE; CANAVAN DISEASE; GENE MUTATION; HUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN INTERACTION; UPREGULATION;

AMIDOHYDROLASES; ASPARTIC ACID; CANAVAN DISEASE; HUMANS; MUTATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; UP-REGULATION;

EID: 77958482877     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.07.017     Document Type: Article

References (24)

1. Surendran S., Kumaresan G. Neurochemical changes and therapeutic approaches in Canavan disease. Neurochemistry of metabolic diseases, lysosomal storage diseases, phenylketonuria and Canavan disease 2007, 119-132. Transworld Research Network, Trivandrum, India. S. Surendran (Ed.).
2. Surendran S. Canavan disease: genomic interaction and metabolic levels. EXCLI J 2005, 4:77-86.
3. Hagenfeldt L., Bollgren I., Venizelos N. N-acetylaspartic aciduria due to aspartoacylase deficiency - a new aetiology of childhood leukodystrophy. J Inherit Metab Dis 1987, 10:135-141.
4. Surendran S., Bamforth F.J., Chan A., Tyring S.K., Goodman S.I., Matalon R. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem. J Child Neurol 2003, 18:809-812.
5. Kaya N., Imtiaz F., Colak D., Al-Sayed M., Al-Odaib A., Al-Zahrani F., et al. Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease. Genet Med 2008, 10:675-684.
6. Surendran S, Rajasankar S. Parkinson's disease: oxidative stress and therapeutic approaches, Neurol Sci 2010, in press. DOI:10.1007/s10072-010-0245-1.
7. Surendran S., Matalon R., Tyring S.K. Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy. Biochem Biophys Res Commun 2006, 345:973-975.
8. Surendran S. Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractility. Mol Biol Rep 2009, 36:201-206.
9. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992, 89:3030-3034.
10. Lin W., Xue H., Liu S., He Y., Fu J., Zhou Z. Genotoxicity of nitric oxide produced from sodium nitroprusside. Mutat Res 1998, 413:121-127.
11. Lin W., Wei X., Xue H., Kelimu M., Tao R., Song Y., et al. Study on DNA strand breaks induced by sodium nitroprusside, a nitric oxide donor, in vivo and in vitro. Mutat Res 2000, 466:187-195.
12. Suzuki T., Yamada M., Ide H., Kanaori K., Tajima K., Morii T., et al. Identification and characterization of a reaction product of 2'-deoxyoxanosine with glycine. Chem Res Toxicol 2000, 13:227-230.
13. Nakano T., Terato H., Asagoshi K., Masaoka A., Mukuta M., Ohyama Y., et al. DNA-protein cross-link formation mediated by oxanine. A novel genotoxic mechanism of nitric oxide-induced DNA damage. J Biol Chem 2003, 278:25264-25272.
14. Lee D-H., Pfeifer G.P. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis 2007, 22:63-67.
15. Okumura F., Lenschow D.J., Zhang D-E. Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization of ISG15 and contributes to effective ISGylation. J Biol Chem 2008, 283:24484-24488.
16. Kaul R., Gao G.P., Balamurugan K., Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 1993, 5:118-123.
17. Klugmann M., Symes C.W., Klaussner B.K., Leichtlein C.B., Serikawa T., Young D., et al. Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 2003, 14:1837-1840.
18. Wang J., Matalon R., Bhatia G., Wu G., Li H., Liu T., et al. Bimodal occurrence of aspartoacylase in myelin and cytosol of brain. J Neurochem 2007, 101:448-457.
19. Namboodiri M.A., Corigliano-Murphy A., Jiang G., Rollag M., Provencio I. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Brain Res Mol Brain Res 2000, 77:285-289.
20. Moore R.A., Le Coq J., Faehnle C.R., Viola R.E. Purification and preliminary characterization of brain aspartoacylase. Arch Biochem Biophys 2003, 413:1-8.
21. Traka M., Wollmann R.L., Cerda S.R., Dugas J., Barres B.A., Popko B. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J Neurosci 2008, 28:11537-11549.
22. Surendran S., Campbell G.A., Tyring S.K., Matalon R. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. Neurobiol Dis 2005, 18:385-389.
23. Kaul R., Casanova J., Johnson A.B., Tang P., Matalon R. Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 1991, 56:129-135.
24. Suzuki T., Yamaoka R., Nishi M., Ide H., Makino K. Isolation and characterization of a novel product, 2'-deoxyoxanosine, from 2'-deoxyguanosine, oligodeoxyribonucleotide and calf thymus DNA treated by nitrous acid and nitric oxide. J Am Chem Soc 1996, 118:2515-2516.